Published in Cancer Weekly, May 27th, 2003
"Cyclophosphamide (CY) combined with granulocyte colony-stimulating factor (G-CSF) is commonly used to mobilize blood progenitor cells to support high dose therapy in patients with multiple myeloma (MM). The optimal dose of CY in this setting is unknown.
"We have retrospectively analyzed mobilization efficiency and need for supportive care in 57 patients with newly diagnosed myeloma, previously treated with VAD±local radiotherapy," scientists writing in the journal Bone Marrow Transplantation report.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly